A 10-year Follow-up of Triple-negative Breast Cancer Patients in Taiwan

作者：Lin Che; Chien Su Yu; Kuo Shou Jen; Chen Li Sheng; Chen Shou Tung; Lai Hung Wen; Chang Tsai Wang; Chen Dar Ren^*

来源：Japanese Journal of Clinical Oncology, 2012, 42(3): 161-167.

DOI：10.1093/jjco/hyr196

• triple-negative breast cancer
• HER2
• estrogen receptor
• progesterone receptor
• survival

This study aimed to investigate whether triple-negative breast cancer has a worse prognosis; here, we present the 10-year follow-up results of triple-negative breast cancer patients in Taiwan. %26lt;br%26gt;We identified 2858 breast cancer patients in Taiwan, of whom 416 (14.6) had triple-negative breast cancer. Data used for analysis were derived from those breast cancer patients who were diagnosed between January 1996 and December 2006. %26lt;br%26gt;In the KaplanMeier analysis, tumor subgroup (triple-negative breast cancer vs. non-triple-negative breast cancer) was a prognostic factor related to 10-year breast cancer death-specific survival and disease-free survival. The results of univariate analysis showed that tumor subgroup was a significant factor related to 10-year disease-free survival and breast cancer death-specific survival, as well as menopausal status, tumor size, lymph node, metastasis, grade, stage, estrogen receptor status, progesterone receptor status and her2/neu gene expression status. Similarly, the multivariate analysis also revealed that tumor subgroup was a significant factor related to 10-year breast cancer death-specific survival and disease-free survival, in addition to tumor size, lymph node, metastasis and grade. %26lt;br%26gt;It was suggested that triple-negative breast cancer patients in Taiwan have worse 10-year survival. Notably, in node-positive patients, triple-negative breast cancer played a prognostic role in 10-year breast cancer death-specific survival.

• 出版日期2012-3